|
(ÁÖ)À¯´ÏÄÚ½á¾îÄ¡ |
[±¹³» ¹ÙÀÌ¿À Á¦¾àȸ»ç] ±Û·Î¹ú »ç¾÷°³¹ß ÀÓ¿ø
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇìµåÇåÅÍ |
17³â¡è |
ä¿ë½Ã |
03.28 |
|
|
ÆÊÄ¿³ØÆà |
[½Å¾à°³¹ß»ç] ½Å±â¼ú°³¹ß
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
10³â¡è |
06.30 |
05.14 |
|
|
ÆÊÄ¿³ØÆà |
[½Å¾à°³¹ß»ç] ½Å±â¼ú°³¹ßÆÀ
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
10³â¡è |
06.30 |
05.10 |
|
|
ÆÊÄ¿³ØÆà |
[±Û·Î¹ú Á¦¾à»ç] Medical Manager
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
8³â¡è |
05.31 |
04.26 |
|
|
ÆÊÄ¿³ØÆà |
[±Û·Î¹ú Á¦¾à»ç] Medical Manager
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
PL/PV/PMS/MD |
8³â¡è |
05.31 |
04.24 |
|
|
ÆÊÄ¿³ØÆà |
[±Û·Î¹ú Á¦¾à»ç] Medical Manager
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
PL/PV/PMS/MD |
8³â¡è |
06.30 |
05.10 |
|
|
(ÁÖ)¿¡ÄÚ½áÄ¡ |
¿Ü±¹°èÁ¦¾àȸ»ç/Local Trial Manager(ÀÓ»ó)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
8³â¡è |
ä¿ë½Ã |
11.29 |
|
|
(ÁÖ)½ºÄ«¿ìÆ®ÆÄÆ®³Ê½º |
±¹³» Áß°ß Á¦¾à»ç BD ÆÀ¿ø ¸ðÁý
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
6³â¡è |
ä¿ë½Ã |
08.30 |
|
|
(ÁÖ)½ºÄ«¿ìÆ®ÆÄÆ®³Ê½º |
±¹³» Áß°ß Á¦¾à»ç RA ÆÀ¿ø ¸ðÁý / 6³â ÀÌ»óÀÚ
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
6³â¡è |
ä¿ë½Ã |
08.30 |
|
|
(ÁÖ)½ºÄ«¿ìÆ®ÆÄÆ®³Ê½º |
±¹³» Áß°ß Á¦¾à»ç ¸¶ÄÉÆà PM ´ë¸® ¹× °úÀå±Þ ¸ðÁý
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) ÀçÇÐ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
5³â¡è |
ä¿ë½Ã |
08.30 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
»óÀåÁ¦¾à»ç ¾à°¡(´ë¸®~°úÀå±Þ)-ASAP
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
01.18 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[¹ÙÀÌ¿À»ç] RA ´ã´çÀÚ (ÀçÅÃÇùÀÇ°¡´É)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
06.08 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
CRA (Clinical Research Associate)
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
09.18 |
|
|
JN Partners |
[¹ÙÀÌ¿À»ç] Àü·«±âȹ ÆÀÀå±Þ
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°æ¿µ/Àü·«±âȹ/ÄÁ¼³Æà |
5³â¡è |
ä¿ë½Ã |
02.16 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
Pharmacovigilance (MI) Specialist / Regulatory Affairs
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
03.14 |
|